Why the study?
How should antiplatelet therapy be managed in patients with recent coronary stents presenting for noncardiac surgery?
How should antiplatelet therapy be managed in patients with recent coronary stents presenting for noncardiac surgery?
Answers are grounded in this paper and cite their sources.
Premature discontinuation of antiplatelet therapy should be avoided in patients with recent coronary stents undergoing noncardiac surgery due to increased risks, particularly with drug-eluting stents.
The management of patients with recent coronary artery stents presenting for noncardiac surgery has become a major topic of interest and concern for all perioperative care givers. The present review will update recent reports and particularly new guidelines as well as recommendations. Based on the available literature, all experts recommend avoiding premature discontinuation of antiplatelet drug therapy if possible except for a few surgical procedures. Drug-eluting stents obviously carry more risks than bare-metal stents.
No takes yet. Share an insight, caveat, or question.
Bornemann‐Cimenti et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: